padrão (~JJ)_(JJ_NN_NN_(NN)?)

#Sem nome próprio
1. Java: (?:[\\w-/]*_(?:[^J]..?\\s|J[^J].?\\s)|^)([\\w-/]*_JJ[RS]?\\s[\\w-/]*_NN[S]?\\s[\\w-/]*_NN[S]?\\s(?:[\\w-/]*_NN[S]?)?)
2. Perl: (?:[\w-/]*_(?:[^J]..?\s|J[^J].?\s)|^)([\w-/]*_JJ[RS]?\s[\w-/]*_NN[S]?\s[\w-/]*_NN[S]?\s(?:[\w-/]*_NN[S]?)?)
	// \w Casa letras, dígitos, ou '_'.
	// 1 e 2 são equivalentes
	// Teve termo terminado com nome próprio (NNP), falso positivo

Sentences Examples:

During_IN 426_CD patient-years_NNS of_IN follow-up_JJ for_IN patients_NNS with_IN standard_JJ criteria_NNS ,_, 3.3_CD acute_JJ chest_NN syndromes_NNS ,_, 1.3_CD cerebrovascular_JJ events_NNS ,_, and_CC 1.1_CD osteonecrosis_NNS per_IN 100_CD patient-years_NNS were_VBD observed_VBN ._. 

HU_NNP was_VBD interrupted_VBN definitely_RB for_IN 12_CD patients_NNS :_: 7_CD underwent_VBD allogeneic_JJ bone_NN marrow_NN transplantation_NN ,_, 1_CD failed_VBD to_TO respond_VB after_IN 2_CD years_NNS of_IN treatment_NN ,_, 1_CD with_IN HbSC_NNP because_IN of_IN a_DT total_JJ Hb_NNP level_NN higher_JJR than_IN 13_CD g\/dL_NNP ,_, 2_CD refused_VBD to_TO pursue_VB the_DT treatment_NN after_IN 1_CD and_CC 2_CD years_NNS ,_, and_CC 1_CD patient_JJ developed_JJ malignancy_NN ._. 

Hydroxyurea_NN was_VBD also_RB transiently_RB stopped_VBD in_IN 3_CD cases_NNS ,_, 2_CD for_IN pregnancy_NN and_CC 1_CD for_IN systemic_JJ lupus_NN syndrome_NN ,_, diagnosed_VBD one_CD year_NN after_IN the_DT beginning_NN of_IN treatment_NN ._. 

We_PRP did_VBD not_RB address_VB the_DT reversibility_NN of_IN chronic_JJ organ_NN damage_NN ;_: it_PRP is_VBZ unknown_JJ whether_IN the_DT inhibition_NN of_IN sickling_NN could_MD affect_VB such_JJ preexisting_JJ lesions_NNS ._. 

There_EX is_VBZ concern_NN that_IN long-term_JJ hydroxyurea_NN therapy_NN may_MD be_VB carcinogenic_JJ or_CC leukemogenic_JJ ,_, because_IN some_DT other_JJ antineoplastic_JJ agents_NNS have_VBP such_JJ effects_NNS ._. 

This_DT observation_NN suggests_VBZ that_IN the_DT increase_NN in_IN MCV_NNP may_MD have_VB a_DT direct_JJ effect_NN on_IN the_DT adhesive_JJ phenotype_NN of_IN sickle_NN cells_NNS and_CC that_IN monitoring_VBG the_DT increase_NN of_IN MCV_NNP may_MD be_VB used_VBN as_IN indirect_JJ evidence_NN of_IN the_DT decrease_NN of_IN the_DT adhesive_JJ phenotype_NN of_IN erythrocytes_NNS in_IN patients_NNS with_IN sickle_JJ cell_NN anemia_NN treated_VBN with_IN hydroxyurea_NN ._. 

Persistent_JJ TCD_NNP elevation_NN signals_VBZ ongoing_JJ stroke_NN risk_NN ._. 

Of_IN the_DT five_CD patients_NNS switched_VBN to_TO hydroxyurea_NN after_IN normalization_NN of_IN their_PRP$ TCD_NNP under_IN transfusion_NN ,_, two_CD developed_JJ velocities_NNS above_IN 200_CD cm\/sec_NN and_CC were_VBD again_RB prescribed_VBN regular_JJ exchange_NN blood_NN transfusions_NNS ._. 

When_WRB the_DT acute_JJ chest_NN syndrome_NN was_VBD diagnosed_VBN ,_, patients_NNS had_VBD hypoxia_NN ,_, decreasing_VBG hemoglobin_NN values_NNS ,_, and_CC progressive_JJ multilobar_JJ pneumonia_NN ._. 

Among_IN patients_NNS with_IN sickle_JJ cell_NN disease_NN ,_, the_DT acute_JJ chest_NN syndrome_NN is_VBZ commonly_RB precipitated_VBN by_IN fat_JJ embolism_NN and_CC infection_NN ,_, especially_RB community-acquired_JJ pneumonia_NN ._. 

Anoxic_JJ brain_NN injury_NN occurred_VBD in_IN three_CD patients_NNS ,_, central_JJ nervous_JJ system_NN hemorrhage_NN in_IN three_CD ,_, and_CC infarction_NN in_IN three_CD ._. 

As_IN compared_VBN with_IN the_DT patients_NNS who_WP underwent_VBD bronchoscopy_NN without_IN incident_NN ,_, the_DT patients_NNS who_WP had_VBD complications_NNS were_VBD more_RBR likely_JJ to_TO present_VB with_IN dyspnea_NN -LRB-_-LRB- 61_CD percent_NN vs._IN 36_CD percent_NN ,_, P_NNP =_SYM 0.04_CD -RRB-_-RRB- and_CC higher_JJR peak_NN respiratory_NN rates_NNS -LRB-_-LRB- mean_NN ,_, 47_CD vs._IN 41_CD per_IN minute_NN ;_: P_NNP =_SYM 0.03_CD -RRB-_-RRB- ._.

The_DT cause_NN of_IN the_DT acute_JJ chest_NN syndrome_NN was_VBD established_VBN in_IN 38_CD percent_NN of_IN episodes_NNS ,_, and_CC pulmonary_JJ infarction_NN was_VBD the_DT presumed_JJ cause_NN in_IN another_DT 16_CD percent_NN ._. 